Alumis Inc (ALMS)vsNovartis AG ADR (NVS)
ALMS
Alumis Inc
$24.69
+7.86%
HEALTHCARE · Cap: $2.91B
NVS
Novartis AG ADR
$147.85
+3.44%
HEALTHCARE · Cap: $282.11B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 235152% more annual revenue ($56.58B vs $24.05M). NVS leads profitability with a 23.9% profit margin vs 0.0%. NVS earns a higher WallStSmart Score of 51/100 (C-).
ALMS
Avoid24
out of 100
Grade: F
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ALMS.
Margin of Safety
-52.5%
Fair Value
$109.60
Current Price
$147.85
$38.25 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Areas to Watch
Trading at 8.6x book value
0.0% revenue growth
0.0% earnings growth
0.0% margin — thin
Expensive relative to growth rate
Grey zone — moderate risk
Revenue declined 0.7%
Earnings declined 9.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : ALMS
The strongest argument for ALMS centers on Debt/Equity.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bear Case : ALMS
The primary concerns for ALMS are Price/Book, Revenue Growth, EPS Growth.
Bear Case : NVS
The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.
Key Dynamics to Monitor
ALMS profiles as a value stock while NVS is a declining play — different risk/reward profiles.
ALMS is growing revenue faster at 0.0% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
NVS scores higher overall (51/100 vs 24/100), backed by strong 23.9% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alumis Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alumis Inc. (ALMS) is an innovative leader in the development and commercialization of high-performance aluminum products, serving critical sectors such as automotive, aerospace, and construction. The company harnesses proprietary technologies to advance material science while adhering to sustainable manufacturing practices, ensuring minimal environmental impact. Focused on research and development, Alumis is strategically positioned to capitalize on emerging market opportunities and expand its diverse product portfolio. With a commitment to operational excellence and stakeholder value, Alumis aims to sustain long-term growth through continuous innovation.
Visit Website →Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?